The Swiss voice in the world since 1935
Top stories
Stay in touch with Switzerland

Study finds well-known drug may slow muscle loss among the elderly

Elderly women doing exercise in a room.
According to the most recent statistics, Swiss men live on average to the age of 81.3, and women to 85.3. © Keystone / Gaetan Bally

Humans are living longer than ever. But age-related diseases such as sarcopenia - the loss of muscle mass - are on the rise. Researchers in Basel say a well-known drug might help delay the aging process.

The Swiss generally live long lives. According to the most recent statistics, Swiss men live on average to the age of 81.3, and women to 85.3. But as a natural part of aging, over time people’s muscles lose tone, shrink and strength dwindles.

This condition, known as sarcopenia, affects every second or third person over 80, reducing their mobility, autonomy and quality of life. The causes of sarcopenia are diverse: from altered muscle metabolism to changes in nerves supplying muscles.

A group of scientists at the University of Basel’s BiozentrumExternal link, which has been investigating the question, has identified a key molecular ‘signature’ of sarcopenia. The team, led by Professor Markus Rüegg, have discovered that mTORC1, which acts as a sensor and controls protein synthesis in the body, also contributes to sarcopenia and its suppression with the well-known drug rapamycin slows age-related muscle wasting.

“Contrary to our expectations, the long-term mTORC1 suppression with rapamycin is overwhelmingly beneficial for skeletal muscle aging in mice, preserving muscle size and strength,” declared Daniel Ham, first author of the study.

To encourage other scientists to further investigate how gene expression in skeletal muscle changes during aging or in response to rapamycin treatment, they have created a web application, SarcoAtlasExternal link, which is supported the Centre for Scientific Computing at the University of Basel (sciCORE).

Currently, there is no effective pharmacological therapy to treat sarcopenia. But the scientists say their study gives hope that in the future it may be possible to slow down age-related muscle wasting with treatments that suppress mTORC1 and thereby extend the autonomy and life quality of elderly people.

Popular Stories

Most Discussed

News

Cyberattacks on Swiss companies increase by 9 per cent

More

Cyberattacks on Swiss companies increase by 9%

This content was published on Swiss companies are increasingly being targeted by cyber criminals. In the past quarter, every single company in this country was the target of a cyber attack an average of 1097 times a week.

Read more: Cyberattacks on Swiss companies increase by 9%
21 minutes of power interruption per end customer in 2024

More

Swiss households faced 21 minutes of power outages in 2024

This content was published on End customers experienced an average of 21 minutes of electricity interruption in 2024. This resulted in 0.34 power outages per capita. The duration of electricity interruptions increased by three minutes compared to the previous year.

Read more: Swiss households faced 21 minutes of power outages in 2024
SMEs struggle to find staff, 'employees have more power'

More

Swiss SMEs struggling to find employees

This content was published on Swiss small and medium-sized enterprises (SMEs) are struggling to find staff, a problem made more acute by the increased bargaining power of employees and increased absenteeism.

Read more: Swiss SMEs struggling to find employees
Demonstrators attack Israeli mission in Geneva

More

Activists deface Israel’s UN mission in Geneva

This content was published on Late on Thursday in Geneva, pro-Palestinian demonstrators attacked the Permanent Mission of Israel to the United Nations in the international organisations district. They poured red paint over the entrance to the building.

Read more: Activists deface Israel’s UN mission in Geneva

In compliance with the JTI standards

More: SWI swissinfo.ch certified by the Journalism Trust Initiative

You can find an overview of ongoing debates with our journalists here . Please join us!

If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR

SWI swissinfo.ch - a branch of Swiss Broadcasting Corporation SRG SSR